MX2009010759A - Derivados de carboxamida imidazolidina como modulares de p2x7. - Google Patents

Derivados de carboxamida imidazolidina como modulares de p2x7.

Info

Publication number
MX2009010759A
MX2009010759A MX2009010759A MX2009010759A MX2009010759A MX 2009010759 A MX2009010759 A MX 2009010759A MX 2009010759 A MX2009010759 A MX 2009010759A MX 2009010759 A MX2009010759 A MX 2009010759A MX 2009010759 A MX2009010759 A MX 2009010759A
Authority
MX
Mexico
Prior art keywords
pain
receptor
modulators
carboxamide derivatives
compounds
Prior art date
Application number
MX2009010759A
Other languages
English (en)
Inventor
David Kenneth Dean
Daryl Simon Walter
Paul John Beswick
Robert James Gleave
Andrew Peter Moses
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0706501A external-priority patent/GB0706501D0/en
Priority claimed from GB0720653A external-priority patent/GB0720653D0/en
Priority claimed from GB0805272A external-priority patent/GB0805272D0/en
Priority claimed from GB0805504A external-priority patent/GB0805504D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MX2009010759A publication Critical patent/MX2009010759A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

La presente invención se refiere a un compuesto de fórmula (I) o una sal farmacéuticamente aceptable del mismo: (ver fórmula I) los compuestos o sales modulan la función del receptor P2X7 y son capaces de antagonizar los efectos de ATP en el receptor P2X7 (antagonistas del receptor P2X7); la invención también provee el uso de dichos compuestos o sales, o composiciones farmacéuticas de los mismos, en el tratamiento o prevención de trastornos/enfermedades mediadas por el receptor P2X7, por ejemplo dolor, inflamación o una enfermedad neurodegenerativa, en particular dolor tal como dolor inflamatorio, dolor neuropátoico o dolor visceral.
MX2009010759A 2007-04-03 2008-04-02 Derivados de carboxamida imidazolidina como modulares de p2x7. MX2009010759A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0706501A GB0706501D0 (en) 2007-04-03 2007-04-03 Novel compounds
GB0720653A GB0720653D0 (en) 2007-10-22 2007-10-22 Novel compounds
GB0805272A GB0805272D0 (en) 2008-03-20 2008-03-20 Novel compounds
GB0805504A GB0805504D0 (en) 2008-03-26 2008-03-26 Compounds
PCT/EP2008/053962 WO2008119825A2 (en) 2007-04-03 2008-04-02 Imidazolidine carboxamide derivatives as p2x7 modulators

Publications (1)

Publication Number Publication Date
MX2009010759A true MX2009010759A (es) 2009-10-28

Family

ID=39673302

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009010759A MX2009010759A (es) 2007-04-03 2008-04-02 Derivados de carboxamida imidazolidina como modulares de p2x7.

Country Status (15)

Country Link
US (1) US7932282B2 (es)
EP (1) EP2142512A2 (es)
JP (1) JP2010523524A (es)
KR (1) KR20090127435A (es)
CN (1) CN101679291A (es)
AU (1) AU2008234855B2 (es)
BR (1) BRPI0809930A2 (es)
CA (1) CA2682649A1 (es)
CR (1) CR11089A (es)
DO (1) DOP2009000231A (es)
EA (1) EA200970912A1 (es)
IL (1) IL201202A0 (es)
MA (1) MA31352B1 (es)
MX (1) MX2009010759A (es)
WO (1) WO2008119825A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2049478B1 (en) * 2006-07-06 2012-05-30 Glaxo Group Limited Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use
GB0724625D0 (en) * 2007-12-18 2008-01-30 Glaxo Group Ltd Novel compounds
WO2011012592A1 (en) * 2009-07-30 2011-02-03 F. Hoffmann-La Roche Ag Dihydropyrimidone amides as p2x7 modulators
SG182261A1 (en) * 2009-12-08 2012-08-30 Univ Vanderbilt Improved methods and compositions for vein harvest and autografting
JP2013521002A (ja) 2010-03-05 2013-06-10 プレジデント アンド フェロウズ オブ ハーバード カレッジ 誘導樹状細胞組成物及びその使用
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
US20140187533A1 (en) * 2011-03-03 2014-07-03 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
ES2574840T3 (es) 2011-07-22 2016-06-22 Actelion Pharmaceuticals Ltd. Derivados de amidas heterocíclicas como antagonistas de receptores p2x7
EP2804865B1 (en) 2012-01-20 2015-12-23 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as p2x7 receptor antagonists
BR112015013463B1 (pt) 2012-12-12 2022-06-14 Idorsia Pharmaceuticals Ltd Derivados de carboxamida indol como antagonistas do receptor de p2x7
AR094053A1 (es) 2012-12-18 2015-07-08 Actelion Pharmaceuticals Ltd Derivados de indol carboxamida como antagonistas del receptor p2x₇
ES2616114T3 (es) 2013-01-22 2017-06-09 Actelion Pharmaceuticals Ltd. Derivados de amida heterocíclica como antagonistas del receptor P2X7
CA2897459C (en) 2013-01-22 2021-03-02 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
KR102424709B1 (ko) 2016-05-31 2022-07-22 칼비스타 파마슈티컬즈 리미티드 혈장 칼리크레인 저해제로서 피라졸 유도체
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
PL3716952T3 (pl) 2017-11-29 2022-05-02 Kalvista Pharmaceuticals Limited Postacie dawkowania zawierające inhibitor kalikreiny osoczowej
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
EP4168393A1 (en) * 2020-06-17 2023-04-26 Merck Sharp & Dohme LLC 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors
CN115650920B (zh) * 2022-11-16 2023-03-31 山东金城柯瑞化学有限公司 制备药物中间体(4s)-1-甲基-2-氧代咪唑啉-4-羧酸叔丁酯的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5024287A (es) 1973-06-28 1975-03-15
JP2830528B2 (ja) 1991-07-25 1998-12-02 東洋インキ製造株式会社 シート状物保持装置
SE9704546D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6492553B1 (en) 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
GB0324498D0 (en) * 2003-07-21 2003-11-26 Aventis Pharma Inc Heterocyclic compounds as P2X7 ion channel blockers
EP2049478B1 (en) 2006-07-06 2012-05-30 Glaxo Group Limited Substituted n-phenylmethyl -5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use

Also Published As

Publication number Publication date
JP2010523524A (ja) 2010-07-15
WO2008119825A3 (en) 2008-12-11
AU2008234855A1 (en) 2008-10-09
US7932282B2 (en) 2011-04-26
DOP2009000231A (es) 2009-11-15
BRPI0809930A2 (pt) 2014-10-07
AU2008234855B2 (en) 2011-01-20
CA2682649A1 (en) 2008-10-09
EA200970912A1 (ru) 2010-02-26
EP2142512A2 (en) 2010-01-13
US20100075968A1 (en) 2010-03-25
WO2008119825A2 (en) 2008-10-09
CR11089A (es) 2010-03-08
CN101679291A (zh) 2010-03-24
KR20090127435A (ko) 2009-12-11
MA31352B1 (fr) 2010-05-03
IL201202A0 (en) 2010-05-17

Similar Documents

Publication Publication Date Title
MX2009010759A (es) Derivados de carboxamida imidazolidina como modulares de p2x7.
ATE502017T1 (de) Pyrazolderivate als p2x7-modulatoren
WO2008119685A3 (en) Oxazolidine and morpholine carboxamide derivatives as p2x7 modulators
WO2008125600A3 (en) Pyrazole derivatives as p2x7 modulators
UA100227C2 (uk) Заміщені n-фенілметил-5-оксопролін-2-аміди як антагоністи p2x7-рецептора та їх застосування
EA025086B9 (ru) Производные индоламида и родственные соединения для использования при лечении нейродегенеративных заболеваний
WO2009106980A3 (en) Indazole derivatives
TNSN07313A1 (en) Substituted thiophene derivatives as glucagon receptor antagonists, preparation and therapeutic uses
WO2012009009A3 (en) Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
MX2011011428A (es) Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
GEP20135806B (en) Lactams as beta secretase inhibitors
MX2010001236A (es) Derivados de 5-fenil-isoxazol-3-carboxamida como moduladores del receptor de potencial transitorio v1 (trpv1).
TW200631945A (en) The aromatic amide derivatives, the pharmaceutical composition comprising the same and its medical application
WO2009036996A3 (en) Small molecule bradykinin b1 receptor antagonists
BR112012023178A2 (pt) ramidinas substituídas como antagonistas de receptor prostaglandina 2
WO2014059232A3 (en) Substituted spiropiperidinyl compounds useful as gpr120 agonists
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
SA520411787B1 (ar) مشتقات بنزيميدازول واستخداماتها
WO2012116176A3 (en) Asymmetric ureas and medical uses thereof
MX2010009462A (es) Derivados de indazol.
MX2013006768A (es) Moduladores de receptor de glucagon.
BR112012023039A2 (pt) pirimidina substituída como um antagonista de receptor prostaglandina d2
MX343165B (es) Agonistas del receptor 5-ht4 para el tratamiento de demencia.
EA201070898A1 (ru) Новое производное хиназолин-2,4-диона и лекарственные композиции на его основе для профилактики и лечения заболевания, обусловленного поражением черепно-мозгового нерва
PH12020550763A1 (en) Pyridinone derivatives and their use as selective alk-2 inhibitors